Zymeworks Appoints Kristin Stafford as Executive VP & CFO, Strengthening Financial Leadership

summarizeSummary

Zymeworks Inc. has appointed Kristin Stafford, formerly of Royalty Pharma, as its new Executive Vice President and Chief Financial Officer, effective April 1, 2026, bringing extensive financial and capital markets expertise to the company.

check_boxKey Events

• New CFO Appointed

  Kristin Stafford has been appointed Executive Vice President, Chief Financial Officer, effective April 1, 2026.

• Experienced Financial Leader

  Ms. Stafford previously served as Senior Vice President, Chief Accounting Officer for Royalty Pharma plc, bringing expertise in strategic planning and capital markets.

• Interim CFO Transition

  Kenneth Galbraith ceased serving as interim CFO, continuing as Chair, CEO, and President, allowing for focused leadership.

• Substantial Compensation Package

  Compensation includes an annual base salary of $520,000, a $52,000 signing bonus, 178,000 stock options, and 169,000 restricted stock units.

auto_awesomeAnalysis

The appointment of Kristin Stafford as Executive Vice President and Chief Financial Officer is a significant strategic move for Zymeworks. Her extensive background at Royalty Pharma, including roles in chief accounting and finance, aligns well with Zymeworks' recent $250 million non-recourse loan from Royalty Pharma and its ongoing asset and royalty aggregation strategy. This hire strengthens the company's financial leadership, allowing CEO Kenneth Galbraith to fully focus on his strategic roles, and signals a commitment to disciplined capital allocation and long-term value creation following recent positive product development news.